Exact Sciences Corporation (EXAS) has recently been rated as a “Hold” by Kyle Mikson from Canaccord Genuity, reflecting a cautious sentiment around the stock as it currently trades at $101.01 with a price target of $105. This development prompts a closer look into the current market position of Exact Sciences, providing investors with insights on future potential as well as risks.
Market / Price Action
The stock of Exact Sciences has demonstrated notable trading activity, marked by a current price of $101.01. Recently, the stock has shown minimal movement, with a slight increase of $0.04, or approximately 0.03% in value. With a market capitalization of around $19.15 billion and a beta of 1.472, the volatility is considerable, emphasizing a tendency to fluctuate more than the broader market. The stock’s 52-week highs and lows were recorded at $160.26 and -$0.84 respectively—indicating a dramatic decline from its previous peak, raising questions among investors regarding recovery. During the last trading session, the stock saw a volume of 6,155,753 shares traded, well above the average volume of 4,206,765, suggesting increased investor interest or speculation.
Short- and Long-Term Performance
Examining the stock’s returns over various timeframes, Exact Sciences displayed promising short-term metrics, achieving an impressive monthly performance of 11.3% and a quarterly performance of 61.77%. However, this has been overshadowed by a 6.96% decline over the year, indicating longer-term challenges that investors need to consider. The recent weekly volatility stands at 4.76%, while monthly volatility is lower at 3.1%, revealing sharper price movements mostly concentrated in the past few weeks. This performance aligns with average trading volumes, which have been significantly above typical levels, particularly with a 10-day average of 21,150,662 compared to a 3-month average of 4,296,515.
Earnings / Financials
Recent earnings disclosures have painted a stark picture for Exact Sciences. The company reported an actual earnings per share (EPS) of -$0.10353, which fell short of the estimated EPS of $0.13, translating to a surprising negative difference of about 179.64%. This is starkly contrasting with the prior quarter, where the reported EPS was $0.22 against an estimate of -$0.02, making it critical for investors to assess the implications of such discrepancies on future performance. The earnings surprise factor raises concerns about the company’s earnings consistency and predictability, highlighting potential operational or market-facing challenges that could impede growth prospects.
Analyst / Consensus View
Taking a closer look at the analyst ratings, Exact Sciences currently holds a consensus rating of “Hold” from a total of 18 ratings—14 of which are “Buy” and 4 “Hold.” Notably, there are no “Sell” ratings among analysts, suggesting a general belief in the company’s potential to stabilize or improve despite the recent setbacks. The average price target stands at approximately $84.33, considerably lower than the recent target set by Canaccord Genuity at $105, hinting at some optimism. The highest price target in this set is $105 while the lowest is projected at $65, reflecting a wide range of expectations regarding future performance.
Stock Grading or Fundamental View
Looking at the Stocks Telegraph Grade, Exact Sciences has been assigned a grade of 53, which indicates a moderate assessment of its fundamental health. The score reflects a balance between strong fundamentals and potential challenges ahead. Factors contributing to this score include the company’s innovation pipeline, competitive position, and recent financial results. However, the magnitude of the recent earnings surprise stresses that investors should watch for signals of recovery or change in operational prowess.
Conclusion
For investors considering Exact Sciences Corporation, the current rating of “Hold” indicates a cautious approach may be appropriate. The stock suits those looking for long-term growth, but potential buyers should weigh operational realities against market expectations. The broader volatility and disappointing earnings coupled with mixed analyst sentiment suggest a complex investment landscape ahead. Risks surrounding earnings consistency and market positioning should not be overlooked, making this stock one to watch closely as it navigates through its challenges and opportunities.